FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Links:
FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleuk…
https://bit.ly/3ZZwq19
Oct-14-2023
